A Phase IIA Study to Determine the Safety and Efficacy of A NCI-Supplied Agent: G3139 (NSC 683428, IND 58842) and Imatinib Mesylate in Patients With Refractory or Relapsed Gastrointestinal Stromal Tumor
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Imatinib (Primary) ; Oblimersen (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 May 2010 Actual patient number (1) added as reported by ClinicalTrials.gov.
- 28 May 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.